Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy With Lenacapavir-containing Regimen
Lenacapavir is the first capsid inhibitor and its use is currently approved for multidrug-resistant human immunodeficiency virus-1 infection. We report that, despite the initial efficacy of a lenacapavir-containing regimen in patients with multidrug-resistant human immunodeficiency virus-2 viruses, virological suppression was not achieved after a year and most patients selected capsid drug resistance-associated mutations.
Authors
- Nadia Valin (ORCID: https://orcid.org/0000-0001-5706-1195)
- Naomi Sayre
- Jade Ghosn (ORCID: https://orcid.org/0000-0003-2914-959X)
- Quentin Le Hingrat (ORCID: https://orcid.org/0000-0001-9017-4941)
- Thibault Saint-Joannis
- Charlotte Charpentier (ORCID: https://orcid.org/0000-0002-6441-7054)
- Sylvie Lariven (ORCID: https://orcid.org/0000-0001-8164-5844)
- Gilles Peytavin (ORCID: https://orcid.org/0000-0002-4359-537X)
- Florence Damond
- Antoine Bachelard (ORCID: https://orcid.org/0000-0002-4682-4916)
- Pierre de Truchis
- Roland Tubiana
- Philippe Morlat
- Diane Descamps
- Cécile Pouderoux
- Mélanie Bertine
- Thomas Montrouge
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Saint-Antoine (FR)
- Hôpital Saint-André (FR)
- Pitié-Salpêtrière Hospital (FR)
- Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR)
- Hôpital Raymond-Poincaré (FR)
- Hôpital Bichat-Claude-Bernard (FR)
- Centre Hospitalier Saint-Denis (FR)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2024-12-31
- DOI
- https://doi.org/10.1093/cid/ciae650
- Citations
- 2
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.78